Delivery Order SPE2DB25D3003-SPE2DB25FPWYG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) at a ceiling value of $3,835.96. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $1,023.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10 mL) on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) under a firm fixed-price contract with a ceiling value of $1,238.72. The contract, which is not set-aside and competitively awarded, is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,585.72 for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed price contract. This non-set-aside award was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10 mL) with a firm fixed price of $3,831.58. The contract was competitively awarded without set-asides and carries an ultimate completion date of September 9, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $1,219.80 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Insulin Aspart 100 Unit/ml in 10ml vials. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by September 10, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,194.80 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed-price contract. The award, issued on September 19, 2025, with an ultimate completion date of September 22, 2025, represents a competitively awarded non-set-aside procurement. Performance of this delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPWYGDelivery Order
The Defense Logistics Agency awarded a $5,030.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL). The contract is non-set-aside and competitively awarded, with performance scheduled for completion by August 13, 2025, at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, holds a significant role in federal medical procurement, particularly supporting Defense Health Agency and military healthcare systems. The parent IDC enables the company to supply a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to support federal healthcare needs. This specific delivery order for insulin exemplifies the company's capability to fulfill critical medical supply requirements through the competitive contracting process, with pricing established on a firm fixed-price basis typical of routine pharmaceutical procurement transactions under the broader vehicle contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 8/12/25 |